phosphate absorption

Sevelamer hydrochloride (Sevelamer HCl) is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption.

Tenapanor (RDX 5791) is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects.

Trisodium phosphate dodecahydrate serves as a corrosion inhibitor for iron in 0.1 M NaClO4 solutions, effective under both aerated and deaerated conditions. Additionally, it acts as an excipient in pharmaceutical formulations, functioning primarily as a pH regulator and buffer. These excipients, also known as pharmaceutical auxiliaries, are substances utilized in the pharmaceutical manufacturing process besides the active pharmaceutical ingredients. They are crucial for enhancing the stability, solubility, and processability of pharmaceutical products. Moreover, pharmaceutical excipients play a significant role in influencing the absorption, distribution, metabolism, and elimination (ADME) of co-administered drugs, thereby affecting their efficacy and safety [1] [2].

Glycerol Kinase (GyK), a bacterial sugar kinase essential for glycerol metabolism, catalyzes the transformation of glycerol into glycerol-3-phosphate (G3P), marking the metabolism's initial step. This enzyme plays a pivotal role in the channel/facilitator-independent cellular absorption of glycerol [1].

NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. The inhibition of NaPi2b, responsible for intestinal phosphate absorption, is considered to reduce serum phosphate levels, making it a promising therapeutic approach for hyperphosphatemia